Meeting
2021 ASCO Annual Meeting
Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.
Authors
Henan Zhang
Mayo Clinic, Rochester, MN
Henan Zhang , Radhika Bansal , Kodi Peterson Martinez , Matthew Hathcock , Zuoyi Shao , Gabriele McCoy , Anatilde Gonzalez-Guerrico , N. Nora Bennani , Jonas Paludo , Yucai Wang , Patrick Johnston , Stephen M. Ansell , Saad Kenderian , Luis F. Porrata , Jose Caetano Villasboas , Yi Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7558)
DOI
10.1200/JCO.2021.39.15_suppl.7558
Abstract #
7558
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma and chronic lymphocytic leukemia.
First Author: Kathryn Cappell
Poster
2019 ASCO Annual Meeting
Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium.
First Author: Jay Y. Spiegel
Poster
2024 ASCO Annual Meeting
Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).
First Author: Alma Habib
Poster
2020 ASCO Virtual Scientific Program
Association of lymphocyte to monocyte ratio with clinical response and survival in patients with relapsed, aggressive non-Hodgkin lymphoma treated with axicabtagene ciloleucel CAR-T.
First Author: Abdullah S. Al Saleh